Jiangsu Aidea Pharmaceutical Co., Ltd (SHA: 688488), a Chinese pharmaceutical company, has announced that its ainuovirine has been granted priority review status by the Center for Drug Evaluation (CDE) for an additional indication. The new indication targets the combination therapy of ainuovirine with nucleoside-based antiretroviral drugs for the treatment of two types of human immunodeficiency virus type 1 (HIV-1) infected adults (weighing over 35 kilograms): (1) patients without a history of antiretroviral therapy, and (2) as an alternative treatment for patients who have received stable antiretroviral therapy, achieved virological suppression (HIV-1 RNA<50 copies/mL), and have no history of treatment failure.
ACC017’s Market Expansion and International Partnerships
ACC017, an HIV integrase strand transfer inhibitor, received approval to treat naïve HIV-1 infected patients in China in June 2021 and was included in the National Reimbursement Drug List (NRDL) in December. Aidea Pharma expanded its international reach by partnering with South Korea-based Kainos Medicine Inc. in November 2020. The partnership led to the establishment of a joint venture, Kaidea Global Pte. Ltd., in Singapore in April 2021, with the mandate to promote the drug overseas. In April 2023, Aidea Pharma further solidified its commitment to the partnership by securing commercial development and promotion rights to ainuovirine and its compound preparations abroad, excluding China mainland, Hong Kong, Taiwan, and South Korea.- Flcube.com
